Amylyx Pharmaceuticals (AMLX) Finished Goods (2022)
Amylyx Pharmaceuticals' (AMLX) quarterly Finished Goods came in at $937000.0 in Q4 2022, up 751.82% quarter-over-quarter from $110000.0 in Q3 2022.
Amylyx Pharmaceuticals (AMLX) Finished Goods (2022) Analysis & Trends
Amylyx Pharmaceuticals' Finished Goods history runs 1 years deep, the most recent figure standing at $937000.0 for Q4 2022.
- On a quarterly basis, Finished Goods changed N/A year-over-year to $937000.0 in Q4 2022; TTM through Dec 2022 was $937000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $937000.0, changed N/A from the prior year.
- Finished Goods grew to $937000.0 in Q4 2022 per AMLX's latest filing, from $110000.0 in the prior quarter.
- Across five years, Finished Goods topped out at $937000.0 in Q4 2022 and bottomed at $110000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Amylyx Pharmaceuticals | 1.94 Bn | 1.94 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 937,000.00 |
| Sep 30, 2022 | 110,000.00 |